A detailed history of Invenomic Capital Management LP transactions in Viatris Inc stock. As of the latest transaction made, Invenomic Capital Management LP holds 3,759,543 shares of VTRS stock, worth $47.1 Million. This represents 2.49% of its overall portfolio holdings.

Number of Shares
3,759,543
Previous 4,290,594 12.38%
Holding current value
$47.1 Million
Previous $45.6 Million 4.3%
% of portfolio
2.49%
Previous 2.29%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.32 - $12.13 $5.48 Million - $6.44 Million
-531,051 Reduced 12.38%
3,759,543 $43.6 Million
Q2 2024

Aug 14, 2024

BUY
$10.05 - $12.02 $3.4 Million - $4.07 Million
338,279 Added 8.56%
4,290,594 $45.6 Million
Q1 2024

May 15, 2024

SELL
$11.27 - $13.53 $21 Million - $25.2 Million
-1,860,565 Reduced 32.01%
3,952,315 $47.2 Million
Q4 2023

Feb 14, 2024

SELL
$8.77 - $10.85 $10 Million - $12.4 Million
-1,139,765 Reduced 16.39%
5,812,880 $63 Million
Q3 2023

Nov 14, 2023

BUY
$9.59 - $11.35 $13.3 Million - $15.8 Million
1,388,362 Added 24.95%
6,952,645 $68.6 Million
Q2 2023

Aug 14, 2023

BUY
$9.02 - $10.29 $15 Million - $17.1 Million
1,661,373 Added 42.57%
5,564,283 $55.5 Million
Q1 2023

May 15, 2023

BUY
$9.2 - $12.26 $17.8 Million - $23.7 Million
1,935,438 Added 98.37%
3,902,910 $37.5 Million
Q4 2022

Feb 14, 2023

BUY
$8.72 - $11.56 $7.97 Million - $10.6 Million
914,106 Added 86.78%
1,967,472 $21.9 Million
Q3 2022

Nov 14, 2022

BUY
$8.48 - $11.13 $8.93 Million - $11.7 Million
1,053,366 New
1,053,366 $8.98 Million
Q1 2021

May 13, 2021

SELL
$13.59 - $18.54 $1.5 Million - $2.05 Million
-110,657 Closed
0 $0
Q4 2020

Feb 17, 2021

BUY
$14.3 - $18.74 $1.58 Million - $2.07 Million
110,657 New
110,657 $2.07 Million

Others Institutions Holding VTRS

About Viatris Inc


  • Ticker VTRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 1,212,669,952
  • Market Cap $15.2B
  • Description
  • Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, i...
More about VTRS
Track This Portfolio

Track Invenomic Capital Management LP Portfolio

Follow Invenomic Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invenomic Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Invenomic Capital Management LP with notifications on news.